Ipsen, BAKX Therapeutics collaborate to broaden their oncology therapy portfolio

EUROPE – Ipsen, a French based company, has entered into collaboration with BAKX Therapeutics with an aim to focus on an oral small-molecule activator of BAX for the potential treatment of leukemia, lymphoma and solid tumors. Under the terms of the deal, Ipsen will collaborate with BAKX Therapeutics to research, develop, manufacture and commercialize BKX-001 in these oncology indications. BAX is a novel target in the apoptosis cell-signaling pathway apoptosis is the naturally occurring process of programmed cell death. Global Immuno- oncology clinical trials market Based on a report from…

Read More